Effects of N-acetyl cysteine on cognitive function in bipolar disorder
Olivia M Dean, Ashley I Bush, David L Copolov, Kristy Kohlmann, Susan Jeavons, Ian Schapkaitz, Murray Anderson-Hunt, Michael Berk
Psychiatry and Clinical Neurosciences | WILEY-BLACKWELL | Published : 2012
Professor Berk has received research support from NIH, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier; has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck and Servier. Dr Bush is a shareholder and consultant for Prana Biotechnology Ltd, and a shareholder of Cogstate Ltd. Dr Dean has received grant or research support from Simons Autism Foundation, Stanley Medical Research Institute, Lilly, NHMRC and an ASBD/Servier grant. Professors Berk, Copolov and Bush are co-inventors on two provisional patents regarding the use of NAC and related compounds for psychiatric indications, assigned to the Mental Health Research Institute. Drs Jeavons, Schapkaitz, Anderson-Hunt and Ms Kohlmann have no biomedical financial interests or potential conflicts of interest. The authors would like to acknowledge support from Barwon Health, the Bendigo Health Care Group and the Mental Health Research Institute.